Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Denis

Showing results (141-150 of 158) with videos related to

Pageof 16
Sort By:
Cell Reports. Medicine|August 2, 2021
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumorsAna Portelinha, Scott Thompson, Roger A Smith, et al.
BMC Medical Research Methodology|December 28, 2018
Mechanisms, contexts and points of contention: operationalizing realist-informed research for complex health interventionsJames Shaw, Carolyn Steele Gray, G Ross Baker, et al.
Journal of Medical Internet Research|June 8, 2026
Artificial Intelligence Governance in Health Systems: Systematic Review of Frameworks and Integrative Model ProposalHassane Alami, Renata Pozelli Sabio, Elsury Johanna Pérez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.
Cancer Research|December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myelomaLaurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.
Cancer|November 2, 2002
An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-upFrank A Vicini, Alvaro Martinez, Gerald Hanks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesQuincy Siu-Chung Chu, Lisa A Hammond, Garry Schwartz, et al.
International Journal of Cancer|January 5, 2002
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trialHarry J de Koning, Anssi Auvinen, Antonio Berenguer Sanchez, et al.
Studies in Health Technology and Informatics|May 25, 2022
Assessing the Quality of Direct-to-Consumer Teleconsultation Services in CanadaJean Noel Nikiema, Eleah Stringer, Marie-Pierre Moreault, et al.
Ciencia & Saude Coletiva|June 2, 2021
Field of practice: LARIISA: smart digital solutions to support decision-making in Family Health Strategy managementRaimundo Valter Costa Filho, José Neuman de Souza, Luiz Odorico Monteiro de Andrade, et al.
Pageof 16

Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Cell Reports. Medicine|August 2, 2021
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumorsAna Portelinha, Scott Thompson, Roger A Smith, et al.
BMC Medical Research Methodology|December 28, 2018
Mechanisms, contexts and points of contention: operationalizing realist-informed research for complex health interventionsJames Shaw, Carolyn Steele Gray, G Ross Baker, et al.
Journal of Medical Internet Research|June 8, 2026
Artificial Intelligence Governance in Health Systems: Systematic Review of Frameworks and Integrative Model ProposalHassane Alami, Renata Pozelli Sabio, Elsury Johanna Pérez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.
Cancer Research|December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myelomaLaurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.
Cancer|November 2, 2002
An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-upFrank A Vicini, Alvaro Martinez, Gerald Hanks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesQuincy Siu-Chung Chu, Lisa A Hammond, Garry Schwartz, et al.
International Journal of Cancer|January 5, 2002
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trialHarry J de Koning, Anssi Auvinen, Antonio Berenguer Sanchez, et al.
Studies in Health Technology and Informatics|May 25, 2022
Assessing the Quality of Direct-to-Consumer Teleconsultation Services in CanadaJean Noel Nikiema, Eleah Stringer, Marie-Pierre Moreault, et al.
Ciencia & Saude Coletiva|June 2, 2021
Field of practice: LARIISA: smart digital solutions to support decision-making in Family Health Strategy managementRaimundo Valter Costa Filho, José Neuman de Souza, Luiz Odorico Monteiro de Andrade, et al.
Pageof 16